The Hematology/Oncology Pharmacy Association has helped establish practical guidance for Investigational Services metrics and site utilization.

The metrics subgroup of the HOPA Investigational drug services (IDS) special interest group recently conducted a survey-based project to help establish practical guidance for IDS metrics and site utlity. Three surveys were sent to HOPA IDS professionals to document how metrics were currently gathered at various sites, categorize and define additional approaches, and create a list of recommended metrics for every IDS site to track. The recommended metrics can serve as a basis for standardization and benchmarking for sites mired in the complexity of research protocols.

The results have been published in the American Journal of Health-Systems Pharmacy.


Authors: Molly Schmidt, PharmD, BCPS, BCOP, CSP; Lisa Janssen Carlson, PharmD, BCOP; Jennifer Murphy, PharmD, BCOP, Sapna R Amin, PharmD, BCOP; Robin Lockhorst, PharmD, BCOP, BCPS; and Kyle Luedtke, PharmD

Read the abstract

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Vorasidenib

Lacy La Fever, PharmD, MS, PGY2 Oncology Pharmacy Resident, and Anastasia Graham, PharmD, MBA, BCOP, Clinical Oncology Specialist, Neuro-oncology, both from Medical University of South Carolina, Charleston, SC, write about vorasidenib (Voranigo).

Image of breast cancer
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Inavolisib

Jessica Yoon, PharmD Candidate from Rutgers University, New Brunswick, NJ, and Grashma Vadakkel, PharmD, BCOP, Clinical Pharmacist at Memorial Sloan Kettering Cancer Center, New York, NY, write about inavolisib (Itovebi)..

Image of stem cell treatment
Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Axatilimab-csfr

Sydney Hunt, PharmD, PGY-1 Pharmacist Resident, and Lindsay Orton, PharmD, BCOP, Stem Cell Transplant and Cellular Therapy Clinical Pharmacist, both from Vanderbilt University Medical Center, Nashville, TN, write about axatilimab-csfr (Niktimvo).